Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

8.110 +0.170 (+2.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 Next >
Alvotech Completes $137 Million Private Share Placement
From Alvotech
Via GlobeNewswire
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
From Alvotech
Via GlobeNewswire
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
From Alvotech
Via GlobeNewswire
Alvotech Completes $59.7 Million Private Placement
From Alvotech
Via GlobeNewswire
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
From Alvotech
Via GlobeNewswire
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
From Alvotech
Via GlobeNewswire
Alvotech Announces Changes to its Leadership Team
From Alvotech
Via GlobeNewswire
Alvotech Secures Financing Facilities of Approximately $136 Million
From Alvotech
Via GlobeNewswire
Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update
From Alvotech
Via GlobeNewswire
Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference
From Alvotech
Via GlobeNewswire
Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022
From Alvotech
Via GlobeNewswire
Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November
From Alvotech
Via GlobeNewswire
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
From Alvotech
Via GlobeNewswire
Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan
From Alvotech
Via GlobeNewswire
Alvotech Appoints Sarah Tanksley as Chief Quality Officer
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.